Skin advanced glycation end products were significantly higher in T2DM subjects with cardiac autonomic neuropathy compared to those without (3.20 vs 2.66, p<0.001).
Cross-Sectional (n=132)
Do skin advanced glycation end products correlate with cardiac autonomic neuropathy in subjects with type 2 diabetes mellitus?
Skin advanced glycation end products are significantly elevated in patients with type 2 diabetes mellitus who have cardiac autonomic neuropathy, suggesting a potential non-invasive marker for this complication.
Absolute Event Rate: 3.2% vs 2.66%
p-value: p=<0.001
INTRODUCTION: Advanced glycation end products (AGEs) are frequently increased in the skin of subjects with type 2 diabetes mellitus (T2DM). This study aimed to examine the correlation of AGEs with cardiac autonomic neuropathy (CAN) in T2DM. METHODS: To this aim, 132 participants (88 men) with a mean age of 64.57 years and a median T2DM duration of 14.5 years were included. Skin AGEs were measured with AGE reader mu connect (Diagnoptics) on the dominant arm (both single and automated triplicate measurements). Diagnosis of CAN, sympathetic and parasympathetic nervous system impairment was based on the four standardised cardiovascular reflex tests (CARTs). RESULTS: On a single measurement, AGEs were increased in subjects with vs. those without CAN (3.20±0.74 vs. 2.66±0.66, p<0.001). As compared with normal results, AGEs were increased for each one of the 4 abnormal CARTs: Valsalva Ratio (3.36±0.67 vs. 2.66±0.72, p=0.004), E/I ratio (3.01±0.72 vs. 2.53±0.68, p=0.001), 30:15 ratio (3.08±0.76 vs. 2.75±0.69, p=0.011), postural hypotension (3.30±0.72 vs. 2.75±0.66, p<0.001). Similar results were obtained for triplicate measurements. DISCUSSION: Among T2DM subjects, skin AGEs appear to increase in the presence of CAN. This holds true both for sympathetic and parasympathetic nervous system impairment.
Papachristou et al. (Thu,) conducted a cross-sectional in Type 2 diabetes mellitus (n=132). Cardiac autonomic neuropathy (CAN) vs. Without CAN was evaluated on Skin advanced glycation end products (AGEs) (p=<0.001). Skin advanced glycation end products were significantly higher in T2DM subjects with cardiac autonomic neuropathy compared to those without (3.20 vs 2.66, p<0.001).